Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul 9;16(7):15592-608.
doi: 10.3390/ijms160715592.

Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis

Gloria Ravegnini  1 , Margherita Nannini  2 , Giulia Sammarini  3 , Annalisa Astolfi  4 , Guido Biasco  5   6 , Maria A Pantaleo  7   8 , Patrizia Hrelia  9 , Sabrina Angelini  10
Affiliations
Review

Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis

Gloria Ravegnini et al. Int J Mol Sci. .

Abstract

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. They are characterized by gain of function mutations in KIT or PDGFRA tyrosine kinase receptors, with their consequent constitutive activation. The gold standard therapy is imatinib that offers a good and stable response for approximately 18-36 months. However, resistance is very common and it is vital to identify new biomarkers. Up until now, there have been two main approaches with focus to characterize novel targets. On the one hand, the focus is on the tumor genome, as the final clinical outcome depends mainly from the cancer specific mutations/alterations patterns. However, the germline DNA is important as well, and it is inconceivable to think the patients response to the drug is not related to it. Therefore the aim of this review is to outline the state of the art of the personalized medicine in GIST taking into account both the tumor DNA (somatic) and the patient DNA (germline).

Keywords: GIST; KIT/PDGFRA mutant GIST; WT-GIST; biomarkers; drug resistance; personalized therapy; polymorphisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The main players in imatinib pharmacokinetics.
See this image and copyright information in PMC

References

    1. Antonescu C.R. The gist paradigm: Lessons for other kinase-driven cancers. J. Pathol. 2011;223:251–261. doi: 10.1002/path.2798. - DOI - PMC - PubMed
    1. Demetri G.D., von Mehren M., Blanke C.D., van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002;347:472–480. doi: 10.1056/NEJMoa020461. - DOI - PubMed
    1. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 2006;368:1329–1338. doi: 10.1016/S0140-6736(06)69446-4. - DOI - PubMed
    1. Demetri G.D., Reichardt P., Kang Y.K., Blay J.Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (grid): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302. doi: 10.1016/S0140-6736(12)61857-1. - DOI - PMC - PubMed
    1. Ricci R., Dei Tos A.P., Rindi G. Gistogram: A graphic presentation of the growing gist complexity. Virchows Arch. 2013;463:481–487. doi: 10.1007/s00428-013-1467-4. - DOI - PubMed

Publication types

MeSH terms

Substances